cerlapirdine

Uses your system voice; voice and rate in settings.

Q5064514Snapshot

≈ 1 min read

Names in other languages

  • Englishcerlapirdine
  • shCerlapirdin
  • СрпскиCerlapirdin
  • azbسرلاپیردین
  • فارسیسرلاپیردین

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Cerlapirdine (USAN; SAM-531, WAY-262,531, PF-05212365) is a drug which was under development by Wyeth/Pfizer for the treatment of cognitive disorders associated with Alzheimer's disease and schizophrenia. In a phase II clinical trial it demonstrated a trend toward efficacy along with a good side effect profile and no incidence of serious adverse events, but no further development has occurred since 2011.

It exerts its effects by acting as a selective 5-HT 6 receptor antagonist.

Cerlapirdine (USAN; SAM-531, WAY-262,531, PF-05212365) is a drug which was under development by Wyeth/Pfizer for the treatment of cognitive disorders associated with Alzheimer's disease and schizophrenia. In a phase II clinical trial it demonstrated a trend toward efficacy along with a good side effect profile and no incidence of serious adverse events, but no further development has occurred since 2011.

It exerts its effects by acting as a selective 5-HT 6 receptor antagonist.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1357689306 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

No external citation was extracted for this revision. That is a statement about the source, not a claim that none exists.